Canine Cognitive Dysfunction: Signs and Vet Care

What canine cognitive dysfunction is

Canine cognitive dysfunction syndrome (CDS) is a progressive neurodegenerative condition with clinical similarities to human Alzheimer's disease. A narrative review by Mihevc and Majdič (2019; PMCID: PMC6582309) characterizes its neuropathology as including amyloid plaque deposition, abnormalities in amyloid precursor protein (APP) processing, cortical atrophy, and disruption of hippocampal and limbic structures — changes that parallel those observed in human Alzheimer's disease, though the two disorders are not identical. Unlike human Alzheimer's patients, the brains of dogs with cognitive dysfunction rarely contain neurofibrillary tangles (Mihevc and Majdič, 2019; PMCID: PMC6582309).

CDS is a diagnosis-of-exclusion with a well-established behavioral phenotype. Mihevc and Majdič (2019; PMCID: PMC6582309) characterize reported signs as including disorientation, anxiety, failure to recognize the owner, altered social behavior, and changes in circadian rhythms. The condition is progressive: Schütt et al. (2015; PMCID: PMC4895687) found that CCD follows an individually variable course, with some dogs declining more rapidly than others, and that no dog diagnosed with CCD in their small longitudinal cohort reverted to a milder or normal cognitive status during the study period.

CDS is substantially underdiagnosed. In a cross-sectional study of 597 dogs, Haake et al. (2024; PMCID: PMC11149356) found that only 15% of dogs showing signs of cognitive decline on validated screening questionnaires had received a formal diagnosis — a pattern the authors characterize as confirming CDS as a highly underdiagnosed condition. Because early signs overlap with what guardians attribute to normal slowing, evaluation is frequently delayed until the condition has progressed considerably.

Normal aging vs cognitive dysfunction

Behavioral and cognitive changes occur along a continuum in aging dogs. Chapagain et al. (2020; PMCID: PMC7494100) measured six behavioral and cognitive factors — problem solving, sociability, trainability, boldness, activity-independence, and dependency — in a sample of 94 aged pet dogs and found that problem-solving performance, sociability, and boldness all declined with increasing age in cross-sectional comparison. These age-associated changes, in the absence of other clinical indicators, reflect typical senescence rather than pathological cognitive dysfunction.

The distinction that separates CDS from normal aging lies in the involvement of core cognitive functions: spatial orientation, social recognition, procedural memory, and circadian regulation. Haake et al. (2024; PMCID: PMC11149356) found that spatial orientation emerged as a key feature in CDS development across all three validated questionnaires studied (CADES, CCAS, CCDR); within the CADES questionnaire specifically, the social interaction domain showed early impairment relative to other domains, suggesting it may mark early cognitive decline. Schütt et al. (2015; PMCID: PMC4895687) documented that dogs with CCD were significantly more likely than dogs with mild cognitive impairment to avoid contact with the owner, show markedly reduced activity, fail to locate dropped food, and walk into doors or walls — signs qualitatively distinct from the slower pace of normal aging.

The DISHAA screening framework

The DISHAA acronym structures owner-reported behavioral observation across the six domains most reliably implicated in CDS. Each domain maps to specific cognitive or neurological systems affected by the disorder. Tracking changes across domains over time — and bringing written records to veterinary appointments — provides the observational foundation for clinical assessment.

No single DISHAA sign confirms cognitive dysfunction — each can have other medical explanations. The pattern across domains, combined with age and veterinary examination, informs the clinical assessment. For context on nighttime restlessness specifically, see the nighttime anxiety guide.

How veterinarians diagnose CCD

CDS is a diagnosis of exclusion. No single blood marker or imaging finding confirms the condition outright. The veterinarian systematically rules out other medical conditions that produce similar signs — hypothyroidism, urinary tract infections (which explain house soiling), pain conditions (which alter behavior and sleep), sensory decline, brain tumors, and metabolic diseases — and when those are excluded and the behavioral pattern fits the DISHAA profile, the clinical picture supports a CDS diagnosis.

Validated questionnaire tools are available to support structured assessment. Haake et al. (2024; PMCID: PMC11149356) compared three commonly used instruments — the Canine Dementia Scale (CADES), the Canine Cognitive Assessment Scale (CCAS), and the Canine Cognitive Dysfunction Rating Scale (CCDR) — in a cross-sectional study of 597 dogs. The study found that the CADES was more sensitive in identifying mild to moderate cognitive impairment, while the CCDR performed particularly well for identifying dogs with severe signs. The choice of screening instrument affected how dogs were classified, illustrating that questionnaire selection has clinical consequences.

Biomarker research has identified elevated plasma amyloid-beta (Aβ42) in dogs with CDS relative to those with mild cognitive impairment or normal cognition. Schütt et al. (2015; PMCID: PMC4895687) found that plasma Aβ42 levels were significantly increased in the CCD group (92.8 ± 24.0 pg/mL) compared to the mild cognitive impairment group (77.0 ± 12.3 pg/mL) and cognitively normal dogs (74.9 ± 10.0 pg/mL), and that higher plasma Aβ40 and Aβ42 were positively correlated with worse scores on the CCDR scale. These biomarkers are not yet part of routine canine clinical diagnosis but represent an active area of veterinary research.

Detailed behavioral records — what has changed, when it started, how it has progressed, specific incidents — provide information no laboratory test can capture. For guidance on whether observed behavioral changes in a senior dog warrant urgent evaluation, the guide on when to seek veterinary evaluation addresses urgency thresholds.

Management: environment, routine, and enrichment

CDS cannot be reversed with current treatments. Mihevc and Majdič (2019; PMCID: PMC6582309) characterize the disorder's neuropathology as including progressive changes — amyloid deposition, cortical atrophy, hippocampal disruption — for which management goals are oriented toward slowing progression and minimizing severity rather than reversal. McKenzie et al. (2022; PMCID: PMC9069128) propose that aging in dogs involves loss of robustness — the ability to maintain optimal physiological functioning — and resilience — the ability to recover from stressors — and that interventions targeting these losses form the basis of geroscience-informed care.

Environmental and behavioral management strategies include:

• Environmental predictability. A dog with degrading spatial cognition benefits from a stable physical environment. Rearranging furniture increases navigational error in animals whose spatial maps are already degrading. Keeping food and water bowls in consistent locations, using nightlights to support navigation in dim conditions, and blocking access to stairs or areas where disorientation may produce injury are practical responses to the spatial disorientation component of CDS.

• Routine consistency. Predictable schedules for meals, walks, and rest serve as an external scaffold for internal processes that are deteriorating. Circadian disruption — which Haake et al. (2024; PMCID: PMC11149356) identified as a heavily weighted domain in CDS questionnaire scoring — may be partially offset by external time cues that reinforce physiological rhythms.

• Cognitive enrichment. Mihevc and Majdič (2019; PMCID: PMC6582309) note that narrative reviews suggest cognitive enrichment alongside an antioxidant-rich diet may have neuroprotective effects in managing CDS progression and severity, though the magnitude of these effects requires further study. Simple enrichment — food puzzles, olfactory exploration, short sessions with familiar cues — engages remaining neural capacity without overwhelming it.

• Social engagement. Gentle, familiar social contact provides comfort even when recognition fluctuates. Environments with excessive novelty — unfamiliar visitors, new settings — impose cognitive demands that a brain with degrading processing capacity handles poorly. Maintaining calm, familiar social routines reduces that load.

• Veterinary pain management. Pain and CDS share overlapping behavioral signs and commonly co-occur in senior dogs. Optimizing pain management as part of a comprehensive senior care plan addresses potential behavioral contributions from musculoskeletal or other pain sources that may compound cognitive signs.

Nutritional and supplement support

Nutritional intervention represents one of the most actively researched management strategies for CDS. Pan et al. (2018; PMCID: PMC6299068) conducted a prospective double-blinded placebo-controlled study in 25 dogs with CDS signs fed a diet containing 6.5% medium-chain triglycerides (MCTs). The study found that dogs fed the MCT diet improved over baseline in all six CDS sign categories by day 90, with five of six categories showing improvement by day 30. Three categories related to brain cognitive functions — disorientation, altered social interaction, and loss of learned behaviors — improved at both timepoints. The placebo control diet did not improve disorientation or altered social interaction. A 9% MCT diet arm failed to improve most signs, attributed primarily to poor palatability and resulting dropout.

MCTs provide an alternative energy substrate for neurons whose glucose metabolism has been impaired by aging. Blanchard et al. (2025; PMCID: PMC12181554) conducted a systematic review examining enriched diets and nutraceuticals for cognitive function in aging dogs and cats. The review found that a diet containing 5.5% MCTs significantly improved executive and visuospatial functions in laboratory dogs. For other nutrient categories, the review found that omega-3 fatty acids showed cognitive benefits in aging pets (especially at higher doses), while antioxidants from plant extracts, plant products, and vitamins E and C used alone were less effective at improving cognitive function, though they may remain useful for stabilizing against oxidative stress. Tryptophan supplementation failed to demonstrate a positive effect on cognitive function across two canine clinical trials (Blanchard et al., 2025; PMCID: PMC12181554).

The association between dietary control and CDS risk also appears in epidemiological data. Katina et al. (2015; PMCID: PMC4772312) found that dogs fed a controlled diet had 2.8 times lower odds of CDS compared to those on uncontrolled diets in a cross-sectional study of 215 dogs — with diet remaining the only statistically significant variable in multivariable analysis. The cross-sectional design precludes causal inference, but the association was robust to adjustment for sex, reproductive status, housing, and body weight.

Specific formulations and amounts should be determined by a veterinarian based on overall health status, weight, existing diet, and any concurrent medications. For a broader look at how supplements fit into anxiety management, the guide to choosing calming supplements provides context — though CDS-related anxiety has an organic neurological basis that makes supplement selection distinct from general anxiety supplementation.

When to start screening (age 7+)

Age is the most consistently identified correlate of CDS. Katina et al. (2015; PMCID: PMC4772312) found that age was positively correlated with cognitive impairment severity scores (r = 0.662, P < 0.0001) in 215 dogs, and confirmed age as the main risk factor for CDS across multiple studies. The same study documented that CCDS prevalence almost tripled in small dogs and quadrupled in medium and large dogs between ages 8 and 13 years. Blanchard et al. (2025; PMCID: PMC12181554) report that CDS prevalence increases with age and may begin as early as 6 years, affecting 14–35% of dogs by age 8. Mihevc and Majdič (2019; PMCID: PMC6582309) note that some studies have reported CDS affecting up to 60% of dogs older than 11 years, though prevalence estimates vary depending on diagnostic criteria.

Earlier-onset clinical presentation in smaller breeds relative to larger breeds has been described. Mihevc and Majdič (2019; PMCID: PMC6582309) note that because larger dog breeds have shorter lifespans than smaller ones, clinical signs of CDS are more often observed and reported in smaller dogs — a result of differential exposure time at older ages rather than differential disease biology. Schütt et al. (2015; PMCID: PMC4895687) found that dogs diagnosed with full CCD were significantly older than cognitively normal or mildly impaired dogs in their clinical sample.

Beginning cognitive screening conversations with the veterinarian around age 7 — and at annual or biannual senior wellness visits thereafter — provides the earliest opportunity to detect emerging signs. Bringing written DISHAA observations to each visit gives the veterinarian a longitudinal behavioral record that examination alone cannot produce. The early intervention window — before significant neurodegeneration has accumulated — is when environmental, dietary, and veterinary management can be initiated at the most favorable point in the disease course.

For a broader look at age-related behavioral changes in senior dogs, the senior dog anxiety guide explores the wider range of anxiety shifts associated with aging — not all of which indicate CDS.

Living with a dog who has CCD

Taylor et al. (2023; DOI: 10.1002/vetr.3266) studied guardian perspectives on caring for dogs with CDS and found that increased attention to treatment — including medications targeting CDS clinical signs — could improve welfare for affected dogs and decrease the clinical burden experienced by guardians. The study noted that CDS care tends to reshape daily household routines; more focused clinical treatment could reduce that burden. These findings show that CDS extends beyond the individual dog.

Nighttime restlessness is among the most disruptive CDS signs for households. Sleep-wake cycle disruption showed among the highest standardized loadings on total CDS questionnaire scores across multiple validated instruments (Haake et al., 2024; PMCID: PMC11149356), reflecting its clinical prominence. Veterinary management options for nighttime disturbance may include behavioral, environmental, and pharmacological approaches — discussion with the veterinarian is appropriate when nighttime restlessness is significantly disrupting household sleep. The nighttime anxiety guide addresses restlessness management broadly, though CDS-driven pacing has an organic neurological basis that may respond differently than other anxiety-related sleep disruption.

House soiling reflects degradation of the learned routines and spatial awareness that supported housetraining — not a behavioral choice. Practical adjustments — increased outdoor access, waterproof bedding, management pads — address the functional consequence without requiring the dog to have cognitive capacity it no longer possesses.

Quality of life assessment is an ongoing veterinary conversation as CDS progresses. The balance between manageable symptoms and unacceptable suffering shifts over time, and veterinarians can help evaluate where a dog stands at each stage. Taylor et al. (2023; DOI: 10.1002/vetr.3266) suggest that greater clinical attention to treatment options — including pharmacological management — could meaningfully improve outcomes for dogs and reduce the burden of care experienced by guardians.

CCD questions and answers